March 6 (Reuters) - ProMIS Neurosciences Inc PMN.TO :
* PROMIS NEUROSCIENCES LEAD PRODUCT CANDIDATE FORALZHEIMER'SDISEASE SHOWS POTENTIAL FOR IMPROVED THERAPEUTIC POTENCY VERSUSOTHER AMYLOID BETA-DIRECTED ANTIBODIES
* PROMIS NEUROSCIENCES INC - PMN310 SHOWED SIMILAR ABILITYTOCROSS BLOOD BRAIN BARRIER AND PENETRATE CENTRAL NERVOUS SYSTEMCOMPARED TO ADUCANUMAB